Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > REGULATORY
REGULATORY
- FY2014 NHI Drug Pricing Reform – Part 4: “Precursor Premium” to Be Introduced, but Hurdle Will Be High; Prices of a Wider Range of New Products to Be Adjusted Based on Average Foreign Prices
February 14, 2014
- FY2014 NHI Drug Pricing Reform – Part 3: Full Introduction of Premium for New Drug Development Rejected Again
February 14, 2014
- PAFSC’s 1st Committee to Review Prasugrel, 3 Combination Antihypertensives on Feb. 24
February 13, 2014
- Upper Limit for Evaluating Rate of Generic Drug Use of DPC Hospitals to Be 60%: Chuikyo’s Recommendation for FY2014 Reform
February 13, 2014
- Prescription, Medication Fees Received for 30-Day or Longer Prescriptions to Be Reduced by 40% at Large Hospitals: FY2014 Medical Fee Reform
February 13, 2014
- Chuikyo Submits Recommendations for FY2014 Revision; Hospitals, Pharmacies with Low Settlement Rates to Face Fee Cuts of Up to 26％
February 12, 2014
- PMDA to Raise Face-to-Face Advising Fees in April
February 12, 2014
- Takeda, 9 Other Drug Makers Join Hands in US NIH Initiative to Quest for New AD, Diabetes, RA Medicines
February 10, 2014
- Chuikyo to Submit Recommendations for FY2014 Medical Fee Revision on Feb. 12
February 10, 2014
- Warning on Interstitial Pneumonia to Be Added to Precautions Section of Package Insert for Rivaroxaban
February 10, 2014
- Bill Payers, Healthcare Providers Agree to Increase Medical Fees, Dispensing Fees
February 7, 2014
- Regulatory Reform Council Selects “Switch-OTC In Vitro Diagnostics” as Target for “International Benchmark Test”
February 7, 2014
- FY2014 NHI Drug Pricing Reform –Part 1: New Rules Will Spur Efforts to Escape Dependence on Long-Listed Drugs, Spark Reorganization of Generic Industry
February 7, 2014
- FY2014 NHI Drug Pricing Reform –Part 2: Introduction of New Rule for Long-Listed Drugs, Elimination of Special Price Cuts Could Spark Shift to New Drugs, Use of AG Strategy
February 7, 2014
- Fiscal Impact Assessment for Key Premium Added to Chuikyo’s Supplementary Opinions for FY2014 Revision
February 6, 2014
- Submission of Draft Bills to Establish Japanese Version of US NIH Approved in Joint Session, “NIH” Will Not Be Part of Name
February 6, 2014
- PMDA’s Next 5-Year Plan to Embrace New Generic Unit, Benchmarks for Review Time
February 5, 2014
- Revised PAL, Pharmacists Law to Take Effect on June 12
February 5, 2014
- PAFSC’s Second Committee Backs Prostate Cancer Drug Enzalutamide
February 4, 2014
- PMDA Raises Caution about Using Factor Xa Inhibitor Xarelto, Citing Risk of Interstitial Pneumonia
February 4, 2014
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…